PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2
Phase 1/2TerminatedDevelopment Stage
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Mar 7, 2018 → Oct 30, 2024
About PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2 is a phase 1/2 stage product being developed by Pfizer for HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03519178. Target conditions include HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03519178 | Phase 1/2 | Terminated |
Competing Products
20 competing products in HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer